Editorial: Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy

European Heart Journal

Volumn 31, Issue 13, 2010, Pages 1551-1553

  Maron, Barry J ^a   Semsarian, Christopher ^b,c,d  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b CENTENARY INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; EDITORIAL; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE MUTATION; HEART LEFT VENTRICLE FUNCTION; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMAN; PRIORITY JOURNAL; TISSUE DOPPLER IMAGING; GENETICS; MUTATION; NOTE;

CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; HETEROZYGOTE DETECTION; HUMANS; MUTATION;

EID: 77954348119     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq111     Document Type: Editorial

References (23)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287: 1308-1320.
2. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2003;42:1687-1713. (Pubitemid 37383745) (Pubitemid 37383745)
3. Maron BJ, Ho CY. Hypertrophic cardiomyopathy without hypertrophy: an emerging preclinical subgroup of genetically affected family members (editorial). JACC Cardiovasc Imaging 2009;2:65-68.
4. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001;104:557-567
5. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardio-myopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008;19: 104-110.
6. Lind JM, Chiu C, Semsarian C. Genetic basis of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther 2006;4:927-934.
7. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M; EUROGENE Heart Failure Project. Hypertrophic cardio-myopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-2232
8. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000;355:58-60.
9. Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG, Seidman CE. Development of left ventricular hypertrophy in adults with hypertrophic cardio-myopathy caused by cardiac myosin-binding protein C mutations. J Am Coll Cardiol 2001;38:315-321.
10. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002;105:2992-2997.
11. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, Quiñones MA, Roberts R, Marian AJ. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001;104:128-130.
12. Cardim N, Perrot A, Ferreira T, Pereira A, Osterziel KJ, Reis RP, Correia JF. Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy. Am J Cardiol 2002;90:128-132.
13. Michels M, Soliman OI, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoor-Krakauer D, ten Cate FJ. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging 2009;2:58-64.
14. Kaneda T, Shimizu M, Ino H, Yamaguchi M, Terai H, Fujino N, Nagata M, Sakata K, Mabuchi H. Changes in cardiac tissue characterization in carriers with gene mutations associated with hypertrophic cardiomyopathy. Int J Cardiol 2005;104: 170-175.
15. Johansson B, Maceira AM, Babu-Narayan SV, Moon JC, Pennell DJ, Kilner PJ. Clefts can be seen in the basal inferior wall of the left ventricle and the interventricular septum in healthy volunteers as well as patients by cardiovascular magnetic resonance. J Am Coll Cardiol 2007;50:1294-1295.
16. Germans T, Wilde AAM, Dijkmans PA, Chai W, Kamp O, Pinto YM, van Rossum AC. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic car-diomyopathy mutations. J Am Coll Cardiol 2006;48:2518-2523.
17. Gandjbakhch E, Gackowski A, Tezenas du Montcel S, Isnard R, Hamroun A, Richard P, Komajda M, Charron P. Early identification of mutation carries in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. Eur Heart J 2010;31:1599-1607. First published on 3 May 2010. doi:10.1093/eurheartj/ehq101.
18. Maron BJ, Zipes DP. 36th Bethesda Conference. Eligibility recommendations for competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 2005; 45:1312-1375.
19. Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited. A comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 2008;52: 1990-1996.
20. Pelliccia S, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi A, Borjesson M, Carrè F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G; Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology; Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Disease of the European Society of Cardiology. Eur Heart J 2005;26:1422-1445.
21. Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298:405-412.
22. Christiaans I, Lakanne dit Deprez RH, van Langene IM, Wilde AA. Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. Heart Rhythm 2009;6:1366-1369.
23. Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. Am J Cardiol 1989;63:1258-1265.